| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sanjay Kalra, Bharti Kalra, Satish Kumar, Amit Sharm. Managing insulin resistance: role of liraglutide. Clinical pharmacology : advances and applications. vol 2. 2012-06-19. PMID:22291496. |
this review discusses the non-glycemic, or extra-pancreatic effects, including insulin sensitization, of liraglutide, a novel glp-1 analog. |
2012-06-19 |
2023-08-12 |
Not clear |
| Liza K Phillips, Johannes B Prin. Update on incretin hormones. Annals of the New York Academy of Sciences. vol 1243. 2012-06-19. PMID:22545749. |
incretins promote insulin secretion, while glp-1 also inhibits glucagon release and gastric emptying, minimizing postprandial glucose excursions. |
2012-06-19 |
2023-08-12 |
Not clear |
| Brian L Furma. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon : official journal of the International Society on Toxinology. vol 59. issue 4. 2012-06-18. PMID:21194543. |
the development of the 'incretin concept' which hypothesised that hormones from the gut contributed to the insulin secretion in response to meals, led to the identification of glucagon-like peptide 1 (glp-1) as an important 'incretin' hormone. |
2012-06-18 |
2023-08-12 |
Not clear |
| Brian L Furma. The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent. Toxicon : official journal of the International Society on Toxinology. vol 59. issue 4. 2012-06-18. PMID:21194543. |
glp-1 not only increases insulin secretion but increases β-cell proliferation and survival, suppresses glucagon secretion, delays gastric emptying and suppresses appetite, all of these actions contributing to a potential anti-diabetic effect. |
2012-06-18 |
2023-08-12 |
Not clear |
| I N Grigor'ev. [UDCA in the treatment of nonalcoholic fatty liver disease]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology. issue 11. 2012-06-18. PMID:22629725. |
as a signaling molecule with system endocrine function, udca improves insulin sensitivity by activating the nuclear farnezoid x-receptor; as a ligand for the tgr5/gpbar-1 receptor, udca is able to stimulate the secretion of glp-1. |
2012-06-18 |
2023-08-12 |
Not clear |
| I N Grigor'ev. [UDCA in the treatment of nonalcoholic fatty liver disease]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology. issue 9. 2012-06-18. PMID:22629789. |
as a signaling molecule with system endocrine function, udca improves insulin sensitivity by activating the nuclear farnezoid x-receptor; as a ligand for the tgr5/gpbar-1 receptor, udca is able to stimulate the secretion of glp-1. |
2012-06-18 |
2023-08-12 |
Not clear |
| Angelo Avogar. [Cardioprotective effects of glucagon-like peptide-1: preclinical and clinical data]. Giornale italiano di cardiologia (2006). vol 12. issue 12 Suppl 2. 2012-06-15. PMID:22158423. |
the main actions of glp-1 are (i) to stimulate insulin secretion; (ii) to inhibit glucagon secretion; (iii) to elicit a delay of gastric emptying time; and (iv) to stimulate neogenesis of insulin-secreting cells. |
2012-06-15 |
2023-08-12 |
Not clear |
| Dale O Kiesewetter, Haokao Gao, Ying Ma, Gang Niu, Qimeng Quan, Ning Guo, Xiaoyuan Che. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. European journal of nuclear medicine and molecular imaging. vol 39. issue 3. 2012-06-15. PMID:22170321. |
glucagon-like peptide type 1 (glp-1) is an incretin peptide that augments glucose-stimulated insulin release following oral consumption of nutrients. |
2012-06-15 |
2023-08-12 |
Not clear |
| Dale O Kiesewetter, Haokao Gao, Ying Ma, Gang Niu, Qimeng Quan, Ning Guo, Xiaoyuan Che. 18F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma. European journal of nuclear medicine and molecular imaging. vol 39. issue 3. 2012-06-15. PMID:22170321. |
the glp-1 system is responsible for enhancing insulin release, inhibiting glucagon production, inhibiting hepatic gluconeogenesis, inhibiting gastric mobility, and suppression of appetite. |
2012-06-15 |
2023-08-12 |
Not clear |
| A H Barnet. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes, obesity & metabolism. vol 14. issue 4. 2012-06-14. PMID:22051096. |
the role of glp-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. |
2012-06-14 |
2023-08-12 |
Not clear |
| A H Barnet. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes, obesity & metabolism. vol 14. issue 4. 2012-06-14. PMID:22051096. |
evidence also suggests a future role for glp-1 mimetics in combination with basal insulin. |
2012-06-14 |
2023-08-12 |
Not clear |
| Cornelia B Landersdorfer, Yan-Ling He, William J Jusk. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. British journal of clinical pharmacology. vol 73. issue 3. 2012-06-12. PMID:22442825. |
mechanism-based population modelling of the effects of vildagliptin on glp-1, glucose and insulin in patients with type 2 diabetes. |
2012-06-12 |
2023-08-12 |
Not clear |
| Cornelia B Landersdorfer, Yan-Ling He, William J Jusk. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. British journal of clinical pharmacology. vol 73. issue 3. 2012-06-12. PMID:22442825. |
to build a mechanism-based population pharmacodynamic model to describe and predict the time course of active glp-1, glucose and insulin in type 2 diabetic patients after treatment with various doses of vildagliptin. |
2012-06-12 |
2023-08-12 |
Not clear |
| Weidong Chai, Zhenhua Dong, Nasui Wang, Wenhui Wang, Lijian Tao, Wenhong Cao, Zhenqi Li. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. vol 61. issue 4. 2012-06-04. PMID:22357961. |
glucagon-like peptide 1 (glp-1) increases tissue glucose uptake and causes vasodilation independent of insulin. |
2012-06-04 |
2023-08-12 |
rat |
| Weidong Chai, Zhenhua Dong, Nasui Wang, Wenhui Wang, Lijian Tao, Wenhong Cao, Zhenqi Li. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. vol 61. issue 4. 2012-06-04. PMID:22357961. |
additional rats received glp-1 or saline for 30 min and muscle insulin clearance/uptake was determined. |
2012-06-04 |
2023-08-12 |
rat |
| Weidong Chai, Zhenhua Dong, Nasui Wang, Wenhui Wang, Lijian Tao, Wenhong Cao, Zhenqi Li. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. vol 61. issue 4. 2012-06-04. PMID:22357961. |
thus, glp-1 may afford potential to improve muscle insulin action by expanding microvascular endothelial surface area. |
2012-06-04 |
2023-08-12 |
rat |
| Anne Kaas, Marie Louise Max Andersen, Siri Fredheim, Philip Hougaard, Karsten Buschard, Jacob Steen Petersen, Carine de Beaufort, Kenneth J Robertson, Lars Hansen, Henrik B Mortensen, Lotte B Nielse. Proinsulin, GLP-1, and glucagon are associated with partial remission in children and adolescents with newly diagnosed type 1 diabetes. Pediatric diabetes. vol 13. issue 1. 2012-06-01. PMID:22118630. |
our aim was to assess the relationship between proinsulin, insulin dose-adjusted haemoglobin a1c (idaa1c), glucagon-like peptide-1 (glp-1), glucagon, and remission status the first year after diagnosis of type 1 diabetes. |
2012-06-01 |
2023-08-12 |
Not clear |
| Takahide Ohishi, Shigeru Yoshid. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert opinion on investigational drugs. vol 21. issue 3. 2012-06-01. PMID:22292451. |
in vitro studies indicate that gpr119 agonists increase intracellular camp levels leading to enhanced glucose-induced insulin release and enhanced incretin hormone glucagon-like peptide 1 (glp-1) secretion. |
2012-06-01 |
2023-08-12 |
Not clear |
| Yong Ook Kim, Detlef Schuppa. When GLP-1 hits the liver: a novel approach for insulin resistance and NASH. American journal of physiology. Gastrointestinal and liver physiology. vol 302. issue 8. 2012-05-29. PMID:22383493. |
when glp-1 hits the liver: a novel approach for insulin resistance and nash. |
2012-05-29 |
2023-08-12 |
Not clear |
| Sho-ichi Yamagishi, Takanori Matsu. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Current pharmaceutical design. vol 17. issue 38. 2012-05-22. PMID:22204436. |
glp-1 not only enhances glucose-evoked insulin release from pancreatic β-cells, but also suppresses glucagon secretion from pancreatic α-cells. |
2012-05-22 |
2023-08-12 |
Not clear |